Sexual Offending: Axis I Comorbidity and Psychopharmacology
New to GIFR? Welcome! Create your account by clicking here
. If you already have an account, please log in
Sexual offenders frequently have comorbid Axis I psychiatric disorders that may be managed using pharmaceuticals. The identification and effective treatment of these conditions can significantly affect the course of sexual offender treatment and diminish recidivism risk. This ATSA Master Class will summarize the nature of psychiatric diagnoses in this population utilizing DSM-5 definitions and criteria. A review and rationale will be presented for incorporating specific “traditional” psychotropic medications as well as testosterone lowering medications into comprehensive treatment programs for sexual offenders.
Martin P. Kafka, MD is a Distinguished Life Fellow of the American Psychiatric Association and serves as Clinical Associate Professor of Psychiatry at Harvard Medical School as well as Senior Clinical Associate at McLean Hospital in Massachusetts. He was selected as a member of the Sexual and Gender Disorders Working Group (Paraphilias Sub-Working Group) of the American Psychiatric Association for the formulation of the Diagnostic and Statistical Manual, 5th Edition. In 2010, Dr. Kafka was awarded the Carnes Award for achievement by the Society for Sexual Health. He has published over 30 peer-reviewed publications.
This training is designed to help you:
- Distinguish dimensional from categorical approaches to psychiatric diagnosis in sex offenders
- Explore how brain development, androgen hormones, and neuropsychiatric disorders interact to contribute to sexual offending
- Develop refined assessment skills to better identify subtle manifestations of psychiatric comorbidities associated with sexual offending
- Assess the role for pharmacological treatments with sexual offenders